Skip to main content
. 2015 Jun 26;55(11):1286–1292. doi: 10.1002/jcph.540

Figure 1.

Figure 1

Mean edoxaban plasma concentration–time curves in study 1. Treatment A, two 30‐mg edoxaban immediate‐release tablets; treatment B, 60 mg edoxaban powder formulation delivered to the distal small bowel; treatment C, 60 mg edoxaban powder formulation delivered to the ascending colon; treatment D, 60 mg edoxaban aqueous suspension delivered to the ascending colon. Error bars represent the standard deviation.